Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PHEROZE TAMBOLI and KANISHKA SIRCAR.
Connection Strength

1.752
  1. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer. 2013 Jun; 32(6):303-11.
    View in: PubMed
    Score: 0.436
  2. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.172
  3. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.150
  4. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
    View in: PubMed
    Score: 0.130
  5. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.130
  6. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 2011 Jan 15; 117(2):290-300.
    View in: PubMed
    Score: 0.093
  7. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest. 2022 05; 102(5):554-559.
    View in: PubMed
    Score: 0.051
  8. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.
    View in: PubMed
    Score: 0.050
  9. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265.
    View in: PubMed
    Score: 0.049
  10. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
    View in: PubMed
    Score: 0.046
  11. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
    View in: PubMed
    Score: 0.038
  12. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.037
  13. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.036
  14. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  15. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.034
  16. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
    View in: PubMed
    Score: 0.034
  17. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.034
  18. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.033
  19. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.033
  20. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.033
  21. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.032
  22. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.032
  23. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.